Scarica l'app Stockscreener
1.73
1.14%
-0.02
Dopo l'orario di chiusura:
1.65
-0.08
-4.62%
Edesa Biotech Inc Borsa (EDSA) Ultime notizie
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar - Simply Wall St
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Reports Fiscal Year 2024 Results - GlobeNewswire
Edesa Biotech Slashes Operating Costs 20%, Secures Government Backing for ARDS Drug Development - StockTitan
Edesa Biotech stock hits 52-week low at $2.02 amid challenges - Investing.com Nigeria
Edesa Biotech stock hits 52-week low at $2.02 amid challenges By Investing.com - Investing.com South Africa
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 192.2% - Defense World
EDSA stock touches 52-week low at $2.08 amid market challenges - Investing.com India
EDSA stock touches 52-week low at $2.08 amid market challenges By Investing.com - Investing.com South Africa
Edesa Biotech (NASDAQ:EDSA) Shares Up 4.7% – Here’s Why - Defense World
EDSA stock touches 52-week low at $2.27 amid market challenges - Investing.com Canada
Edesa Leaps as CEO Boosts Holdings - Baystreet.ca
Edesa Biotech CEO invests $5 million in company By Investing.com - Investing.com India
Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire
Edesa Biotech to Present at Global Conferences - Nasdaq
Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewswire
Edesa Biotech Partners with Wainwright for Share Sales - TipRanks
Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38 - MSN
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? - MSN
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
500: Something went wrong - Investing.com UK
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Zacks Small Cap Research
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
Myroslav Chwaluk | Mergers & Acquisitions Lawyer in Toronto | People - Fasken
A. Wojtek BaraniakPolish-speaking Corporate/Commercial lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa Biotech (NASDAQ:EDSA) Receives Buy Rating from HC Wainwright - Defense World
Allied gaming executive Choi buys shares worth $778k By Investing.com - Investing.com
Bioventus exec sells over $14k in company stock By Investing.com - Investing.com
Edesa's Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - StockTitan
Edesa’s Paridiprubart Selected For U.S.-Funded Platform Trial In General ARDS - Contract Pharma
Comparing Assertio (NASDAQ:ASRT) and Edesa Biotech (NASDAQ:EDSA) - Defense World
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Rises By 32.1% - Defense World
Anixa Biosciences director buys shares worth over $1,000 By Investing.com - Investing.com
French jet engine maker Safran gets Italy's clearance to buy Microtecnica - Yahoo Finance UK
Edesa Biotech Shareholders Approve Board and Compensation PlansTipRanks.com - TipRanks
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo - Smartkarma
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024 - InvestorPlace
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):